Showing posts with label human osteobalsts. Show all posts
Showing posts with label human osteobalsts. Show all posts

Friday, April 04, 2014

Osteoblast Activators and Musculoskeletal Disease Assays

We now have the ability to precisely test human Osteoblast activating agents. Tools available include:

  1.  Live cell screening
  2. Quantibody Bone Metabolism Arrays
  3. PCR
  4. Flow Cytometry
  5. Immunostaining
  6. Western Blotting
This means we can generate data that provides you a clear picture of the effects of small molecules/compounds on the activation, expansion and migration of Osteoblasts. Here's an example.

Image: Activin A expression from Osteoblasts treated with Activators vs Controls

We will soon be releasing a turn-key assay for Osteoporosis Drug Discovery. We can also run custom assays that fit your specific requirements. To learn more, you can call (612-801-1007) or e-mail: pshuster@neuromics.compshuster@neuromics.com). Thank you. Pete Shuster, CEO and Owner, Neuromics.

Sunday, December 01, 2013

In vivo Like Cell Based Assays!

Save 100 USD on our Potent, Pure and Easy to Culture Stem and Progenitor Cells

We continue to design in vivo like behaviors into our  Cell Based Assays.
Our goal is to enable you to make better research decisions earlier
in your discovery process.

These assays are engineered using our proven, potent and easy to culture eSC and Adult Human Stem Cells and Progenitors.

UCB Derived hMSC differentiated to Osteoblast. Note the calcium depositions.

***December Promotions-New Products-Save 100 USD+ 
on Primary and Stem Cells, Media, Markers and Growth Factors***
I'll be posting videos of our in vivo like assays with specific quantitative data here soon.

Sunday, November 24, 2013

Microelectrodes for On-Chip Manipulation of Human Mesenchymal Stem Cells

Amping up Osteogenesis Assays for Drug Discovery

Neuromics and Vitrobiopharma are developing kinetic, differentiation asssays for improving the Drug Discovery process for Osteo-related diseases like Osteoporosis and Osteoarthritis. We have the ability to develop in vivo like assays with quantitative endpoints. The foundation of these assays are potent, easy to culture and cost effective Human Mesenchymal Stem Cells (hMCSCs).

I wanted to share an excellent study using our hMSCs for Osteogenesis Assays: Hsiao, Y.-S., Kuo, C.-W. and Chen, P. (2013), Multifunctional Graphene–PEDOT Microelectrodes for On-Chip Manipulation of Human Mesenchymal Stem Cells. Adv. Funct. Mater., 23: 4649–4656. doi: 10.1002/adfm.201203631. This represents a novel approach for Osteogenesis Assays and illustrates the capabilities of our hMSCs.
Absract: All-solution-processed multifunctional organic bioelectronics composed of reduced graphene oxide (rGO) and dexamethasone 21-phosphate disodium salt (DEX)-loaded poly(3,4-ethylenedioxythiophene) (PEDOT) microelectrode arrays on indium tin oxide glass are reported. They can be used to manipulate the differentiation of human mesenchymal stem cells (hMSCs). In the devices, the rGO material functions as an adhesive coating to promote the adhesion and alignment of hMSC cells and to accelerate their osteogenic differentiation. The poly(L-lysine-graft-ethylene glycol) (PLL-g-PEG)-coated PEDOT electrodes serve as electroactive drug-releasing electrodes. In addition, the corresponding three-zone parallel devices operate as efficient drug-releasing components through spatial-temporal control of the release of the drug DEX from the PEDOT matrix. Such devices can be used for long-term cell culturing and controlled differentiation of hMSCs through electrical stimulation.

Protocols: The hMSCs (Neuromics, Edina, MN) used in experiments were at passage 3-9. Each passage of hMSCs was maintained on the TCPS dishes with a pre-coating of Geltrex reduced growth factor basement membrane matrix (Invitrogen, CIBCO, NY). All hMSCs were maintained in the growth medium, Dulbecco's modified Eagle's medium-low glucose (DMEM-LG) supplemented with mesenchymal cell growth supplement (MSCGM, Lonza) containing L-glutamine, penicillin, and streptomycin, and incubated in an atmosphere containing 5% CO2 at 37 °C. The medium was replenished every 3 to 4 days. For osteogenic differentiation, the hMSCs were cultured in the osteogenesis induction medium, DMEM-LG supplemented with mesenchymal stem cell osteogenesis kit (Chemicon, Cat. No. SCR028), and incubated on the TCPS dishes (control) and test devices. To study the drug release from the devices, hMSCs were cultured in the osteogenesis induction medium in the absence of DEX. The fresh medium was replaced every 2 to 3 days.


Figure: a–d) Osteocalcin expression in hMSCs cultured on rGO–PEDOT microelectrode arrays of various sizes (rGO–PEDOT-20, rGO–PEDOT-50, rGO–PEDOT-100), revealed through immunofluorescence staining. Cells were cultured for 9 days in osteogenesis induction medium in the absence of DEX; drug release was modulated electrically through three cycles of ES (three-day interval); osteocalcin (green) revealed the bone matrix and DAPI (blue) revealed the nucleus. e) Enlarged view of immunofluorescence of osteocalcin expression in hMSCs cultured on rGO–PEDOT-100. Arrows indicated the formation of bone matrix nodules. Scale bar: 100 μm. f) Schematic representation of some bioelectronic features integrated into our rGO–PEDOT devices. doi: 10.1002/adfm.201203631

Conclusion: Authors explored the effect of the dimensions of the rGO–PEDOT microelectrode arrays on the cell spreading and expression of differentiation; whereas the smaller rGO–PEDOT-20 array exhibited better cell alignment ability, the larger rGO–PEDOT-100 exhibited better performance at inducing osteocalcin expression in hMSCs. They also found that using three-zone parallel devices made it possible to release drugs at three points in time. This concept could presumably be extended to release different types of drugs at different lineages on defined patterns. Eventually, such devices might be applicable in tissue engineering and regenerative medicine.

I plan on frequent updates on ours and others development of Osteogenesis Assays for Drug Discovery.

Saturday, March 02, 2013

Increasing Returns in Drug Discovery

"Harnessing the Power of Cells"
 
Cell based assays presentation v1_03_2012 from Pete Shuster

This presentation provides an executive overview of how our Solutions can improve Drug Discovery processes.

Why Consider our Solutions?
Research proven solutions used by large Pharmas, Biotechs, Academic and Government Labs. 2500+ customers-Publications/Testimonials
Lower per well costs-we can aggressively discount cells and media
Customer success focused                                  
Expert technical support
Detailed protocols and methods
Quick replacements and reorders
Large expert resource network
Published expert input
Non confidential; customer feedback and data sharing through social media outlets and blogs